Ursodeoxycholic Acid Combined With Low Dose Glucocorticoid in the Treatment of PBC With AIH Features II

Inclusion Criteria: 1. Patients aged 18-75 years; 2. The diagnosis of PBC is clear and does not meet the Paris criteria for diagnosing PBC overlap AIH, but it needs to meet 3xULN \< ALT \< 5xULN or 3xULN \< AST \< 5xULN or 1.3xULN \< IgG \< 2xULN, and liver pathological biopsy excludes moderate or higher interface inflammation; 3. Agreed to participate in the trial, and assigned informed consent. Exclusion Criteria: 1. The presence of hepatitis A, B, C, D, or E virus infection; 2. Patients with presence of cirrhosis; 3. Patients with presence of fulminant liver failure; 4. Liver damage caused by other reasons: such as primary sclerosing cholangitis, non-alcoholic steatohepatitis, drug induced liver disease or Wilson's disease; Pregnant and breeding women and women of childbearing age in need of reproduction; 5. Severe disorders of other vital organs, such as severe heart failure, cancer; 6. Parenteral administration of blood or blood products within 6 months before screening; 7. Recent treatment with drugs having known liver toxicity; 8. Taken part in other clinic trials within 6 months before enrollment. 9. patients with contraindications of glucocorticoid